Middle East: Febrile and fragmented

Mon, 05/14/2012 - 15:16 EDT - FT.com - Analysis

Comments

Treatment of minorities – and the ability to curb sectarianism within and among nations – poses a crucial test for the emerging order. By David Gardner

Original article
Login to post comments

Iran nuclear deal sparks anger in Middle East, Israeli prime minister calls it a ‘historic mistake’
JERUSALEM — Israel’s prime minister harshly condemned the international community’s nuclear deal with Iran on Sunday while Western allies in the Persian Gulf were conspicuously quiet, reflecting the jitters felt throughout the Middle East over Iran’s acceptance on the global stage. Elsewhere, many welcomed the agreement as an important first step toward curbing Iran’s suspect nuclear program.
Seismic events will shape the Middle East
America may wish to pivot towards Asia and Europe may be turned inward, but the Middle East offers no respite, writes David Gardner
Seismic events will shape the Middle East
America may wish to pivot towards Asia and Europe may be turned inward, but the Middle East offers no respite, writes David Gardner
Middle East: Harder to bear
Middle East In a region that gave birth to all three Abrahamic faiths, fears for the future are growing among Christians as regimes that gave them protection yield to something less certain, writes David Gardner
Looking for Emerging Market Yield? Consider These 3 Telecom Giants
ETF Database submits: As the turmoil in the Middle East spreads, many investors have fled a number of market sectors for the safe havens of gold and silver in order to wait out the storm. Arguably, no one sector has been more impacted than the emerging markets which have seen tremendous outflows thanks to a broad flight to quality by numerous investors around the globe.
The Emerging German-Russian Axis
Submitted by Charles Gave via Gavekal Dragonomics,
The pecking order behind Unilever Chief Executive Officer Paul Polman just got clearer
This week’s announcement of Dave Lewis’s departure to Tesco Plc leaves 29-year Unilever veteran Alan Jope as CEO Paul Polman’s most obvious successor, according to analysts and management experts.
Mobius: Middle East –youthful reawakening
Article written by Prieur du Plessis, editor of the Investment Postcards from Cape Town blog.The paragraphs below come courtesy of Mark Mobius, emerging markets guru and executive chairman of Templeton Asset Management.
Cepheid’s TB Test Looks Promising
Zacks.com submits: A study regarding Cepheid’s (CPHD) Xpert MTB/RIF test, which is meant for the detection of tuberculosis ((TB)), was published in the latest edition of the New England Journal of Medicine. The study was aimed at comparing the sensitivity and specificity of the Xpert MTB/RIF with the standard currently used.
AbbVie’s AML Treatment Produces Positive Phase-II Trial Results
AbbVie Inc (NYSE:ABBV) announced positive Phase-II trial results for its pipeline compound venetoclax as a treatment for acute myelogenous leukemia (AML) at the American Society of Hematology’s (ASH) 56th Annual Meeting session on Sunday. The company spent $3.3 billion in expenses related to research and development during the nine-month period ending September 2014. These expenses are about 13% greater than the amount spent on research and development in fiscal year 2013 (FY13).

Main menu

Secondary menu

Middle East: Febrile and fragmented

Related

Latest

Markets Map

Follow Us

Secondary menu